aerovatetx.com - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים AVTE

The current R&D pipeline of Aerovate Therapeutics (AVTE) is being revised due to a pause in trials of its lead drug. The YoY revenue growth rate over a trailing 12-month period reflects asset dynamics, with the latest value recorded as 0.00. Business stability relies on robust distribution of inhalation products and strategic alliances with clinics, which enhances the startup's investment appeal for a potential merger.
פילוחי נתונים אנליטיים מרוכזים עבור Aerovate Therapeutics, Inc. (AVTE)

This indicator measures the percentage change in revenue over the trailing twelve months, neutralizing short-term volatility to identify a sustainable business growth vector. Analyzing the LTM sales volume trend allows for an assessment of the effectiveness of Aerovate Therapeutics (AVTE) in pursuing new therapeutic directions amid the need to protect capital from competitor expansion following the completion of key trials.